EpiAxis nominates EP-1302.0 as lead candidate for IND advancement, renamed epiresatide
EpiAxis Therapeutics is pleased to announce the nomination of epiresatide as its lead candidate for IND advancement. Epiresatide is a generation 2.1 stapled peptide specifically targeting nuclear LSD1, which offers a novel mode of action. Designed to address the...
EpiAxis Therapeutics to present at Biotech Showcase 2023
EpiAxis Therapeutics, a leading LSD1 company with a focus on the treatment, diagnosis and monitoring of cancer and the prevention of its recurrence, is presenting at Biotech Showcase™ 2023. EpiAxis CEO Dr Jeremy Chrisp will discuss the company's focus on developing...
EpiAxis enters agreement with Seattle Children’s Research Institute
EpiAxis Therapeutics has signed a material transfer agreement (MTA) with Seattle Children’s Research Institute that will help researchers study a new approach to treating paediatric brain cancer. As part of the agreement, EpiAxis Therapeutics will supply its lead...
There is currently no therapy to fight recurrent, metastatic breast cancer, which is the major source of death in women with breast cancer. Furthermore, current first-line treatments have extensive side-effects.We are determined to fix that.
Professor Sudha Rao
Founder at EpiAxis Therapeutics